𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia

✍ Scribed by Joachim L. Schultze; John W. Donovan; J. G. Gribben

Publisher
Springer
Year
1999
Tongue
English
Weight
187 KB
Volume
77
Category
Article
ISSN
0946-2716

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Alemtuzumab as treatment for residual di
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt

Detection of minimal residual disease in
Detection of minimal residual disease in acute leukemia by flow cytometry
✍ Dario Campana; Elaine Coustan-Smith πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 289 KB πŸ‘ 2 views

Patients with acute leukemia in clinical remission may still have up to 10 10 residual malignant cells (the upper limit of detection by standard morphologic techniques). Sensitive techniques to detect minimal residual disease (MRD) may allow better estimates of the leukemia burden and help the selec